Suppression of IFN-Induced Transcription Underlies IFN Defects Generated by Activated Ras/MEK in Human Cancer Cells

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Christian, Sherri L ^a   Zu, Dong ^a   Licursi, Maria ^a   Komatsu, Yumiko ^a   Pongnopparat, Theerawat ^a   Codner, Dianne A ^a   Hirasawa, Kensuke ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAS PROTEIN; RECOMBINANT ALPHA INTERFERON;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BIOINFORMATICS; BTN3A3 GENE; CANCER CELL; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL METABOLISM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA MICROARRAY; GBP2 GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN CELL; IFIT2 GENE; IMMUNE RESPONSE GENE; MAP2 GENE; MMP7 GENE; NONHUMAN; RIGI GENE; STAT2 GENE; TRANSCRIPTION REGULATION;

ANTIVIRAL AGENTS; BUTADIENES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERONS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR SEQUENCE ANNOTATION; NEOPLASMS; NITRILES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RAS PROTEINS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 84866131809     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044267     Document Type: Article

References (72)

1. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, et al. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
2. Coffey MC, Strong JE, Forsyth PA, Lee PW, (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
3. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, et al. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
4. Balachandran S, Porosnicu M, Barber GN, (2001) Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 75: 3474-3479.
5. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW, (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362.
6. Farassati F, Yang AD, Lee PW, (2001) Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3: 745-750.
7. Bergmann M, Romirer I, Sachet M, Fleischhacker R, Garcia-Sastre A, et al. (2001) A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res 61: 8188-8193.
8. Cascallo M, Capella G, Mazo A, Alemany R, (2003) Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 63: 5544-5550.
9. Goetz C, Everson RG, Zhang LC, Gromeier M, (2010) MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. Mol Ther 18: 1937-1946.
10. Puhlmann J, Puehler F, Mumberg D, Boukamp P, Beier R, (2010) Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 29: 2205-2216.
11. Dhillon AS, Hagan S, Rath O, Kolch W, (2007) MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290.
12. Cully M, Downward J (2008) SnapShot: Ras Signaling. Cell 133: 1292-1292 e1291.
13. Schubbert S, Shannon K, Bollag G, (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308.
14. Downward J, (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
15. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW, (2007) Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 15: 1522-1530.
16. Battcock SM, Collier TW, Zu D, Hirasawa K, (2006) Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 80: 4422-4430.
17. Christian SL, Collier TW, Zu D, Licursi M, Hough CM, et al. (2009) Activated Ras/MEK inhibits the antiviral response of alpha interferon by reducing STAT2 levels. J Virol 83: 6717-6726.
18. Noser JA, Towers GJ, Sakuma R, Dumont JM, Collins MK, et al. (2006) Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol 80: 7769-7774.
19. Novick D, Cohen B, Rubinstein M, (1994) The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77: 391-400.
20. Schindler C, (1999) Cytokines and JAK-STAT signaling. Exp Cell Res 253: 7-14.
21. Randall RE, Goodbourn S, (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1-47.
22. Horvath CM, Stark GR, Kerr IM, Darnell JE Jr, (1996) Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Mol Cell Biol 16: 6957-6964.
23. Levy DE, Kessler DS, Pine R, Darnell JE Jr, (1989) Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro. Genes Dev 3: 1362-1371.
24. de Veer MJ, Holko M, Frevel M, Walker E, Der S, et al. (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69: 912-920.
25. Noser JA, Mael AA, Sakuma R, Ohmine S, Marcato P, et al. (2007) The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther 15: 1531-1536.
26. Okeoma CM, Lovsin N, Peterlin BM, Ross SR, (2007) APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445: 927-930.
27. Saha S, Sugumar P, Bhandari P, Rangarajan PN, (2006) Identification of Japanese encephalitis virus-inducible genes in mouse brain and characterization of GARG39/IFIT2 as a microtubule-associated protein. J Gen Virol 87: 3285-3289.
28. Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, et al. (2010) 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468: 452-456.
29. Perwitasari O, Cho H, Diamond MS, Gale M Jr, (2011) Inhibitor of kappaB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection. J Biol Chem 286: 44412-44423.
30. Chin KC, Cresswell P, (2001) Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc Natl Acad Sci U S A 98: 15125-15130.
31. Carter CC, Gorbacheva VY, Vestal DJ, (2005) Inhibition of VSV and EMCV replication by the interferon-induced GTPase, mGBP-2: differential requirement for wild-type GTP binding domain. Arch Virol 150: 1213-1220.
32. Greber UF, Way M, (2006) A superhighway to virus infection. Cell 124: 741-754.
33. Radtke K, Dohner K, Sodeik B, (2006) Viral interactions with the cytoskeleton: a hitchhiker's guide to the cell. Cell Microbiol 8: 387-400.
34. Dehmelt L, Halpain S, (2005) The MAP2/Tau family of microtubule-associated proteins. Genome Biol 6: 204.
35. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, et al. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5: 730-737.
36. Maric M, Arunachalam B, Phan UT, Dong C, Garrett WS, et al. (2001) Defective antigen processing in GILT-free mice. Science 294: 1361-1365.
37. Rhodes DA, Stammers M, Malcherek G, Beck S, Trowsdale J, (2001) The cluster of BTN genes in the extended major histocompatibility complex. Genomics 71: 351-362.
38. McCusker D, Wilson M, Trowsdale J, (1999) Organization of the genes encoding the human proteasome activators PA28alpha and beta. Immunogenetics 49: 438-445.
39. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R, (2011) Interaction of tumor cells with the microenvironment. Cell Commun Signal 9: 18.
40. Shmulevitz M, Pan L-Z, Garant K, Pan D, Lee PWK, (2010) Oncogenic Ras Promotes Reovirus Spread by Suppressing IFN-beta Production through Negative Regulation of RIG-I Signaling. Cancer Research 70: 4912-4921.
41. Guo Z, Garg S, Hill KM, Jayashankar L, Mooney MR, et al. (2005) A distal regulatory region is required for constitutive and IFN-beta-induced expression of murine TLR9 gene. J Immunol 175: 7407-7418.
42. Lu R, Au WC, Yeow WS, Hageman N, Pitha PM, (2000) Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation. J Biol Chem 275: 31805-31812.
43. Ward SV, Samuel CE, (2003) The PKR kinase promoter binds both Sp1 and Sp3, but only Sp3 functions as part of the interferon-inducible complex with ISGF-3 proteins. Virology 313: 553-566.
44. Wei L, Sandbulte MR, Thomas PG, Webby RJ, Homayouni R, et al. (2006) NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity. J Biol Chem 281: 11678-11684.
45. Bovolenta C, Driggers PH, Marks MS, Medin JA, Politis AD, et al. (1994) Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc Natl Acad Sci U S A 91: 5046-5050.
46. Huang M, Qian F, Hu Y, Ang C, Li Z, et al. (2002) Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nat Cell Biol 4: 774-781.
47. Muchardt C, Yaniv M, (2001) When the SWI/SNF complex remodels the cell cycle. Oncogene 20: 3067-3075.
48. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR, (2007) An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449: 1073-1077.
49. Pelaez IM, Kalogeropoulou M, Ferraro A, Voulgari A, Pankotai T, et al. (2010) Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma cells. Int J Biochem Cell Biol 42: 911-920.
50. Rico-Bautista E, Flores-Morales A, Fernandez-Perez L, (2006) Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev 17: 431-439.
51. Liu B, Mink S, Wong KA, Stein N, Getman C, et al. (2004) PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 5: 891-898.
52. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
53. Zhang F, Hatziioannou T, Perez-Caballero D, Derse D, Bieniasz PD, (2006) Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353: 396-409.
54. Stawowczyk M, Van Scoy S, Kumar KP, Reich NC, (2011) The interferon stimulated gene 54 promotes apoptosis. J Biol Chem 286: 7257-7266.
55. Goldstein D, Laszlo J, (1986) Interferon therapy in cancer: from imaginon to interferon. Cancer Res 46: 4315-4329.
56. Goldstein D, Laszlo J, (1988) The role of interferon in cancer therapy: a current perspective. CA Cancer J Clin 38: 258-277.
57. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S, (2002) Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100: 2926-2931.
58. Zitzmann K, Brand S, De Toni EN, Baehs S, Goke B, et al. (2007) SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 67: 5025-5032.
59. Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, et al. (2000) Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. Hematol J 1: 7-14.
60. Shang D, Liu Y, Ito N, Kamoto T, Ogawa O, (2007) Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance. Cancer Sci 98: 1259-1264.
61. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, et al. (1998) Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91: 570-576.
62. Sebolt-Leopold JS, (2000) Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19: 6594-6599.
63. Thompson N, Lyons J, (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5: 350-356.
64. Hirasawa K, Kim A, Han HS, Han J, Jun HS, et al. (2003) Effect of p38 mitogen-activated protein kinase on the replication of encephalomyocarditis virus. J Virol 77: 5649-5656.
65. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, et al. (2002) Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62: 1696-1701.
66. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
67. Carvalho BS, Irizarry RA, (2010) A framework for oligonucleotide microarray preprocessing. Bioinformatics 26: 2363-2367.
68. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
69. Smyth GK, Michaud J, Scott HS, (2005) Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21: 2067-2075.
70. Zeeberg B, Qin H, Narasimhan S, Sunshine M, Cao H, et al. (2005) High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics 6: 168.
71. Sturn A, Quackenbush J, Trajanoski Z, (2002) Genesis: cluster analysis of microarray data. Bioinformatics 18: 207-208.
72. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.